NUCLEUS 24 AUDITORY BRAINSTEM IMPLANT SYSTEM

Implant, Auditory Brainstem

FDA Premarket Approval P000015

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the nucleus 24 auditory brainstem implant (abi) system, which is intended to restore useful hearing via electrical stimulation of the cochlear nucleus. The device is indicated for individuals 12 years of age or older, who have been diagnosed with neurofibromatosis type 2 (nf2). Implantation may occur during first or second-side tumor removal, or in patients with previously removed acoustic tumors bilaterally. Because the surgical procedure for tumor excision and electrode placement eliminates residual hearing, preoperative audiological criteria are not relevant. Prospective implant recipients and their families should have appropriate expectations, regarding the potential benefits of an auditory brainstem implant and should be highly motivated to participate in the postopearative rehabilitation process.

DeviceNUCLEUS 24 AUDITORY BRAINSTEM IMPLANT SYSTEM
Classification NameImplant, Auditory Brainstem
Generic NameImplant, Auditory Brainstem
ApplicantCochlear Americas
Date Received2000-03-29
Decision Date2000-10-20
Notice Date2000-12-12
PMAP000015
SupplementS
Product CodeMHE
Docket Number00M-1659
Advisory CommitteeEar Nose & Throat
Expedited ReviewYes
Combination Product No
Applicant Address Cochlear Americas 13059 East Peakview Avenue centennial, CO 80111
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P000015Original Filing
S048 2022-09-07 Real-time Process
S047 2022-04-26 Normal 180 Day Track
S046 2021-06-21 135 Review Track For 30-day Notice
S045 2020-11-12 30-day Notice
S044
S043 2020-07-15 30-day Notice
S042 2019-11-13 30-day Notice
S041
S040
S039 2019-07-31 30-day Notice
S038
S037 2019-06-06 30-day Notice
S036
S035 2019-01-30 30-day Notice
S034 2018-11-01 Normal 180 Day Track
S033 2018-08-13 30-day Notice
S032 2018-04-13 30-day Notice
S031 2018-02-15 30-day Notice
S030 2018-02-02 30-day Notice
S029 2018-01-02 30-day Notice
S028 2018-01-02 30-day Notice
S027 2017-11-13 Normal 180 Day Track
S026 2017-08-25 135 Review Track For 30-day Notice
S025 2017-08-07 30-day Notice
S024 2017-07-26 30-day Notice
S023 2017-06-21 Real-time Process
S022 2017-06-07 30-day Notice
S021 2017-05-16 30-day Notice
S020 2017-04-10 30-day Notice
S019 2017-03-23 30-day Notice
S018 2016-11-23 30-day Notice
S017 2016-11-23 30-day Notice
S016 2016-10-12 Normal 180 Day Track
S015 2016-09-22 30-day Notice
S014 2016-06-23 30-day Notice
S013
S012 2015-12-18 Normal 180 Day Track
S011 2009-10-13 Special (immediate Track)
S010 2007-12-03 Real-time Process
S009
S008 2006-09-05 30-day Notice
S007
S006 2005-03-09 30-day Notice
S005 2003-06-24 Real-time Process
S004 2002-12-06 Normal 180 Day Track
S003 2002-10-31 Normal 180 Day Track
S002 2001-07-23 Normal 180 Day Track
S001 2001-06-22 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
09321502020404 P000015 012

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.